跳至主要内容
临床试验/CTRI/2023/05/052953
CTRI/2023/05/052953尚未招募Phase 3 4

COMPARATIVE EVALUATION OF LOCAL DRUG DELIVERY GEL CONTAING EXTRACTS OF MURRAYA KOENIGII WITH THAT OF CHLORHEXIDINE GEL AS AN ADJUNCT TO SCALING AND ROOT PLANING IN MANAGEMENT OF MODERATE CHRONIC PERIODONTITIS : A RANDOMIZED CONTROLLED TRIAL.

Swargiya Dadasaheb Kalmegh Smruti dental College And hospital1 个研究点 分布在 1 个国家目标入组 72 人开始时间: 2023年5月30日最近更新:
适应症

试验速览

阶段
Phase 3 4
状态
尚未招募
发起方
入组人数
72
试验地点
1
主要终点
efficacy of Murraya Koenigii gel in patients with Moderate Chronic Periodontitis as an adjunct to scaling and root planing.

研究概览

简要总结

Chlorhexidine (CHX) is one of the most effective antimicrobial agents for plaque control. Local side effects associated with the use of chlorhexidine induce tooth staining, alteration of taste sensation and costly to the patient. Despite the immense benefit of chlorhexidine gluconate as an antiplaque agent, the search continues for active ingredients that could prevent dental inflammation without affecting the biological equilibrium within the oral cavity. Currently, use of herbal products in dentistry is increasing. This can be attributed to their ease of availability, low cost, and fewer side effects. One such herb with wide medicinal importance is Murraya Koenigii, commonly known as curry leaves. It is well established to have antimicrobial, antiemetic, antidiabetic, antiulcer, antioxidative, cytotoxic, and phagocytic activity. Chlorophyll component in curry leaves has been reported as an anticariogenic agent and it also helps to reduce halitosis. The antibacterial effect of Murraya Koenigii extract has been proven to be effective against an array of Gram-positive, Gram-negative periodontal pathogens. Therefore, Murraya Koenigii extract mouth rinse has been used as an alternative to chlorhexidine mouthwash.

To the best of our knowledge no such study has been carried out comparing the use of Murraya Koenigii in gel form as a local drug delivery agent in the management of Chronic periodontitis. Therefore, the aim of this study will be to assess the efficacy of Murraya Koenigii gel as a local delivery agent in the management of moderate chronic periodontitis

研究设计

研究类型
Interventional
分配方式
Computer generated randomization
盲法
Participant and Investigator Blinded

入排标准

年龄范围
20.00 Year(s) 至 50.00 Year(s)(—)
性别
All

入选标准

  • Patients with pocket probing depth ≥ 5mm with localized/generalized periodontitis not indicated for surgery.

排除标准

  • Patients who received any antibiotic therapy in the last 6 months.
  • Patients who received any chemotherapeutic mouth rinses/oral irrigation during the past 1 month.
  • Patients who received any surgical or nonsurgical periodontal therapy, 6 months prior to the start of the study.
  • Patients with allergies to any of medications which will be used in the study.
  • Pregnant or Lactating women.
  • Patients who are smokers/alcoholic.

结局指标

主要结局

efficacy of Murraya Koenigii gel in patients with Moderate Chronic Periodontitis as an adjunct to scaling and root planing.

时间窗: 30th day, 90th day

次要结局

  • efficacy of Murraya Koenigii gel over chlorhexidine gel in patients with Moderate Chronic Periodontitis as an adjunct to scaling and root planing.(30th day, 90th day)

研究者

发起方
Swargiya Dadasaheb Kalmegh Smruti dental College And hospital
申办方类型
Research institution and hospital

研究点 (1)

Loading locations...

相似试验

已完成
不适用
克拉霉素干混悬剂人体生物等效性研究
CTR2023176980
进行中(未招募)
不适用
克拉霉素分散片(0.25g)在中国健康受试者中餐后给药条件下随机、开放、单剂量、两制剂、三序列、三周期、部分重复交叉生物等效性试验克拉霉素适用于治疗对其敏感的致病菌引起的感染,包括: 1.下呼吸道感染(如支气管炎、肺炎):由副流感嗜血杆菌、卡他莫拉菌、肺炎链球菌、嗜肺军团杆菌、百日咳杆菌、金黄色葡萄球菌、肺炎支原体或肺炎衣原体等引起; 2.上呼吸道感染(如咽炎、鼻窦炎):由化脓性链球菌、流感嗜血杆菌、卡他莫拉菌、肺炎链球菌、草绿色链球菌、淋球菌、金黄色葡萄球菌、庆氧菌等引起; 3.皮肤及软组织感染(如毛囊炎、蜂窝组织炎、丹毒):由金黄色葡萄球菌,化脓性链球菌、痤疮丙酸杆菌、草绿色链球菌等引起; 4.局部或弥散性感染:由鸟型分枝杆菌或细胞内分枝杆菌引起的局部或弥散性感染,以及由海龟分枝杆菌、意外分枝杆菌或堪萨斯分枝杆菌引起的局部感染; 5.混合感染:克拉霉素适用于 CD4 淋巴细胞数小于或等于 100/mm3 的 HIV 感染患者预防由弥散性鸟型分枝杆菌引起的混合感染; 6.根除幽门螺杆菌:存在胃酸抑制剂时,克拉霉素也适用于根除幽门螺杆菌,从而减少十二指肠溃疡的复发; 7.牙源性感染:治疗由敏感致病菌引起的牙源性感染。
CTR20220103
进行中(未招募)
不适用
克拉霉素分散片(0.25g)在中国健康受试者中空腹给药条件下随机、开放、单剂量、两制剂、三序列、三周期、部分重复交叉生物等效性试验
CTR2022010439
已完成
不适用
克拉霉素颗粒人体生物等效性研究
CTR2021261172
进行中(未招募)
不适用
克拉霉素颗粒在空腹及餐后条件下的人体生物等效性试验
CTR2021230972